AC Immune (ACIU) Stock Price
AC Immune Price
Revenue at AC Immune has contracted by 7.1% per year over the past 12 years to 3.57 M CHF. Earnings per share have grown at 26.1% per year over the last 5 years. For AC Immune, the net margin of -1,971.6% is up versus -7,732.6% a few years ago. The consensus 12-month price target for AC Immune is 5.83 CHF, about 177.6% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
AC Immune stock price
AC Immune business model & stock analysis
Frequently asked questions about AC Immune
The business model of AC Immune SA focuses on developing innovative therapeutics and diagnostics to prevent and treat neurodegenerative diseases, such as Alzheimer's disease. AC Immune SA employs a unique approach combining precision medicine and immunotherapy to target misfolded proteins, like tau and amyloid-beta, which play a crucial role in the progression of these diseases. By leveraging its proprietary platforms and strategic partnerships, AC Immune SA aims to bring potential disease-modifying treatments and accurate diagnostic tools to market, addressing the unmet needs in neurodegenerative disorders.
AC Immune SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of AC Immune SA in the market are companies such as Biogen Inc., Roche Holding AG, and Eli Lilly and Company.
AC Immune SA is a leading biopharmaceutical company with a rich history and background. Founded in 2003, AC Immune has been steadfastly committed to discovering, developing, and delivering innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease. With a strong focus on precision medicine, AC Immune strives to address unmet medical needs by targeting pathological proteins such as tau and alpha-synuclein. Leveraging its state-of-the-art proprietary platforms and strategic collaborations, the company has made significant progress in advancing its robust pipeline of therapeutics and diagnostics. AC Immune's unwavering dedication to improving patients' lives continues to drive its pioneering research and development efforts in the field of neurodegenerative diseases.
AC Immune SA, a renowned biotech company, has achieved several significant milestones. It has successfully advanced its proprietary clinical-stage pipeline, focusing on neurodegenerative diseases like Alzheimer's and Parkinson's. AC Immune has also established strategic collaborations with renowned pharmaceutical companies, reinforcing its position in the industry. The company has achieved positive clinical trial results for its innovative therapeutic candidates, demonstrating promising efficacy and safety profiles. AC Immune's dedication to pioneering precision medicine approaches and its strong focus on research and development have been instrumental in its continuous growth and recognition in the field of neurodegenerative diseases.
AC Immune SA is primarily present in multiple countries and regions across the globe. Some of the key areas where the company has a significant presence include Switzerland, where AC Immune SA is based, as well as the United States, where it operates through its subsidiaries. Additionally, AC Immune SA has a growing presence in various European countries, including France, Germany, and the United Kingdom. With its global reach, AC Immune SA is continuously expanding its footprint and partnerships to advance its mission in pioneering precision medicine for neurodegenerative diseases.
AC Immune SA represents a set of core values and a corporate philosophy that guide its actions and decision-making. The company is committed to advancing precision medicine to combat neurodegenerative diseases. AC Immune SA focuses on the discovery, development, and commercialization of innovative therapies targeting misfolded proteins, with a particular emphasis on Alzheimer's disease. By leveraging its deep scientific expertise and collaborative approach, AC Immune SA strives to make a meaningful impact on patients' lives. The company's dedication to scientific excellence, integrity, innovation, and patient-centeredness drives its pursuit of groundbreaking treatments and solutions for neurodegenerative disorders.
Analysts currently set an average price target of 5.83 CHF for the AC Immune stock (median: 5.83 CHF), implying +177.6 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the AC Immune stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AC Immune to generate revenue of 20.22 M CHF and earnings per share of -0.42 CHF.
Converted at the current exchange rate, the AC Immune share trades at 2.25 EUR (2.10 CHF).
The AC Immune share (ACIU) is listed on 4 stock exchanges, including: NASDAQ (ACIU), Frankfurt (IMR.F), München (IMR.MU), Düsseldorf (IMR.DU).
AC Immune SA is a biotechnology company that focuses on the development of innovative therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company covers several areas, including research and development, clinical development, production, and distribution of medications. Currently, AC Immune SA is working on several product candidates in different phases of clinical development. This includes a range of monoclonal antibodies and small molecules that target specific neurodegenerative receptors and proteins such as beta-amyloid and tau protein. AC Immune SA's product candidates aim to eliminate disease-causing proteins by supporting the immune defense of the body or directly inhibiting protein formation. A major product of AC Immune SA is the monoclonal antibody ACI-24, which targets beta-amyloid, a buildup of proteins that plays an important role in Alzheimer's disease. ACI-24 is currently in phase II of clinical development. Another product candidate of AC Immune SA is the monoclonal antibody ACI-35, which targets tau protein, which promotes the formation of β-amyloid. ACI-35 is in preclinical development. Furthermore, AC Immune SA utilizes its proprietary platform technology to advance the development of biomarkers that can be used in the diagnosis of neurodegenerative diseases. AC Immune SA has a number of partnerships with pharmaceutical companies such as Roche, Genentech, and Johnson & Johnson to market and further develop its products and technologies. AC Immune SA pursues a business model that aims to manufacture patented therapeutic agents tailored to the needs of patients with neurodegenerative diseases. This business model also includes close collaboration with other pharmaceutical companies and academic institutions to unlock additional clinical benefits and accelerate commercialization. Through its product pipeline and platform technology, as well as strategic partnerships, AC Immune SA offers its customers and patients a comprehensive portfolio of therapeutic products and services aimed at revolutionizing the treatment of neurodegenerative diseases. Overall, AC Immune SA has earned an excellent reputation through its continuous search for innovative solutions and its commitment to collaboration in a highly competitive market.
The expected revenue of AC Immune is 20.22 M CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of AC Immune is -42.29 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of AC Immune is currently -5.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AC Immune stock.
The price-to-sales ratio (P/S) of AC Immune is currently 10.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AC Immune stock.
The Eulerpool Quality Score for AC Immune is 1/10.
The ISIN of AC Immune is CH0329023102. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AC Immune is A2AR5F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AC Immune is ACIU. The ticker symbol is used to trade AC Immune shares on the stock exchange.
AC Immune stock
AC Immune Peer Group
AC Immune Ticker
AC Immune FIGI
All fundamentals and in-depth analysis of AC Immune
Our stock analysis for AC Immune stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.